Mapping and predicting mortality from systemic sclerosisMuriel Elhaï, Carlos Alberto von Mühlen, Lidia P Ananieva et al.|Annals of the Rheumatic Diseases|2017Cited by 699
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) groupSuzana Jordan, Thierry Zénone, Jörg H. W. Distler et al.|Annals of the Rheumatic Diseases|2014Cited by 432
Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for ScreeningMaria Grazia Lazzaroni, Ilaria Cavazzana, Enrico Colombo et al.|The Journal of Rheumatology|2017Cited by 127
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohortCarina Mihai, Dorota Krasowska, Oliver Distler et al.|Lara D. Veeken|2019Cited by 29
Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR studyCécile Trottet, Claudia Ickinger, Manuel Schürch et al.|npj Digital Medicine|2025Cited by 5